Albumin Therapy Development for Stroke

Albumin is an important plasma protein, accounting for approximately 60% of total blood proteins. It is synthesized in the liver and has various functions in the body such as binding and transporting lipids and lipid-soluble substances, supplementing nutrition, and maintaining plasma colloid osmotic pressure. Extensive preclinical studies suggest that albumin, when administered at moderate to high doses, exerts a neuroprotective effect on the occurrence and development of ischemic stroke. The neuroprotective effects of albumin are attributed to its multiple mechanisms, including antioxidant, anti-inflammatory, and anti-edema properties, as well as its ability to maintain vascular integrity and regulate glial cell metabolism.

Fig. 1. Serial neuroimaging was performed in animals treated with saline and albumin. Fig. 1 Serial neuroimaging in saline- and albumin-treated animals. (Wang, et al., 2007)

Our Albumin Therapy Development Services

Ace Therapeutics is committed to advancing albumin therapy for stroke through comprehensive preclinical research services. Working closely with research institutions and pharmaceutical companies, we can customize albumin therapy development solutions to meet our clients' needs. Our integrated approach includes rigorous preclinical studies and a seamless internal regulatory process to ensure the accuracy of experimental results.

Preclinical Evaluation of Albumin Therapy

We provide reliable animal models of ischemic stroke to evaluate the efficacy and safety of albumin therapy.

Services	Service Details
Evaluation of therapeutic efficacy	Delineate the spatial evolution of the infarct volume using serial T2-weighted imaging and diffusion-weighted imaging (DWI) in albumin-treated animals. Characterize motor and exploratory behavior. Histological measurement of infarct size. Assess BBB integrity using IgG immunohistochemistry. Measure cerebral blood flow using a laser Doppler flowmetry (LDF). Double-labeling immunohistochemical staining for the co-localization of albumin with activated microglial markers, inflammatory markers, oxidative stress markers, and apoptotic markers.
Dose-response study	Determine the optimal dose range of albumin therapy for neuroprotection and functional recovery in stroke models.
Therapeutic window study	Determine the time window within which albumin therapy can be effectively administered after stroke. Evaluate the dose-dependent effects of albumin at different time points.
Molecular mechanisms of drug action	Antioxidant effects: Measure oxidative stress markers and free radical scavenging. Endothelial effects: Evaluate anti-apoptotic effects on vascular endothelial cells. Anti-edema effects: Analyze the anti-edema effect of albumin by measuring the volumetric ipsilateral versus contralateral hemispheres. Metabolic effects: Investigate the role of albumin in maintaining astrocytic health and function.

Formulation and Drug Delivery Optimization

We can help clients develop advanced albumin formulations to improve the stability, bioavailability, and therapeutic efficacy of albumin therapy.

Services	Service Details
Intravenous formulations	Design albumin solutions for safe and effective intravenous administration.
Development of albumin-based drug delivery systems	Develop albumin-based nanoparticles to deliver therapeutics across the BBB to ischemic brain tissue.

At Ace Therapeutics, we are committed to helping our clients accelerate the development of albumin therapy through innovative research and strategic collaborations. Contact us today to learn more about our albumin therapy development services and how we can support your stroke research and therapeutic development.

Reference

Wang, R., et al. (2007). Albumin reduces blood-brain barrier permeability but does not alter infarct size in a rat model of neonatal stroke. Pediatric research, 62(3), 261-266.

All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.